Osteoarthritis treatment

CONTEXT

10 to 15 % of people are concerned by metabolic, traumatic or aged dependent osteoarthritis with a prevalence of 10 % per year.

No cure is currently available and only symptomatic treatments are reimbursed by health insurances.

DESCRIPTION

A strong protective effect against metabolic osteoarthritis was obtained by a molecule with a marketing authorization on another indication. This was shown on 100 % of rats exhibiting metabolic syndrome that all develop metabolic osteoarthritis.

These early results will undergo preclinical proof of concept studies for efficacy in the next months on rats with early metabolic osteoarthritis and/or early traumatic osteoarthritis.

COMPETITIVE ADVANTAGES

• First cure for metabolic osteoarthritis
• Known molecule

MARKETS AND APPLICATIONS

Rheumatology

• Metabolic osteoarthritis on metabolic syndrome patients (MetS) and/or traumatic osteoarthritis

DEVELOPMENT STAGE

TRL 4: in vivo protective results on rats

Proof of curative effect on rats are to come shortly

INTELLECTUAL PROPERTY

Published on February 1st, 2018

TARGET PARTNERSHIP

Patent licensing

CONTACT

Thomas BLUM

Business Developer

+33 (0)6 17 06 68 07

thomas.blum@sayens.fr